Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter double-blind randomized placebo-controlled trial of IDEC-C2B8 in childhood-onset nephrotic syndrome (JSKDC10)
jRCT1091220380Completed
- Sponsor
- Kobe University Hospital
- Start
- Sep 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial in Idiopathic nephrotic syndrome (INS) and nephrosis comparing Rituximab (IDEC-C2B8) with Placebo (2 arms). Primary endpoints: Relapse-free period and Safety - adverse events and adverse drug reactions. Started Sep 2018; status: completed.
02
Drugs
rituximab
03
Conditions
Idiopathic nephrotic syndrome (INS)nephrosis
Beyond the preview
Go deeper on jRCT1091220380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1091220380.